ALZN Alzamend Neuro Inc

$ALZN what the fuck happened overnight? just dont get this fucking stock. it took 3 months to go up and then 1 day killed

$ALZN Over one later and no clinical trial started by Harvard after 10 years of research.---Lithium Depletion is an Early Hallmark: Brain lithium levels were high in cognitively healthy individuals, but severely depleted in those with Mild Cognitive Impairment (MCI) and early Alzheimer’s. Amyloid Plaque Sequestration: As toxic amyloid-beta proteins form, they act like a sponge—binding to and trapping free lithium in the brain. This deprives neurons, glia, and microglia of the essential trace lithium needed to maintain normal synaptic function and suppress neuroinflammation. Reversal of Cognitive Loss in Preclinical Models: When researchers administered an amyloid-evading lithium compound—specifically Lithium Orotate—at ultra-low micro-doses, it bypassed plaque trapping, reduced neuroinflammation, restored synaptic connections, and reversed memory loss in mice without any cellular toxicity.

$ALZN plans a presentation by its principal investigator at the ISMRT Conference on Sep 29.

$ALZN 2. But he was always bothered by a missing link in what came to be known as the amyloid hypothesis of Alz: Some people can have brains riddled with amyloid plaques and have relatively intact cognition, while others who have similar amounts of amyloid are severely impaired. The recent findings provide an explanation. By showing that amyloid binds to and neutralizes lithium and that aging individuals can vary in their baseline lithium levels, Yankner’s team may be starting to understand the imperfect correlation between amyloid and disease symptoms. It was a finding 10 years in the making. It required overcoming several technological hurdles, such as the ability to detect very low levels of a metal not previously thought to exist naturally in the body; the development of mouse models that could demonstrate the impact of a loss of lithium in the brain; and the creation of a new screening platform to test a series of lithium "COMPOUNDS" to find those that can evade lithium binding.

$ALZN Bruce Yankner has been working on Alzheimer's for over 35 years, over 10 years on the therory of lithium. Yet, even with all that research, he is still at least 5 years behind Alzamend in terms of clinical trials.--1. At the time, amyloid was thought to be an inert byproduct of Alzheimer’s disease. But Yankner found that neurons that overexpress the amyloid precursor gene had begun to die. He had discovered that far from being a harmless byproduct, amyloid was in fact toxic to neurons, suggesting that it might play a causal role in Alzheimer’s. That finding, first made in the early 1990s, together with the genetics of the disease, has shaped decades of Alzheimer’s research and is foundational to amyloid-targeting drugs such as lecanemab and donanemab, which were recently approved by the FDA. Yankner’s work has extended into other areas since then, including the basic science of aging and gene regulation in the brain, Parkinson’s disease, Down syndrome, and psychiatric disease.

$ALZN so these fuckers hvae to do manipulatoin in every fucking stock on my list, dont they?

$ALZN come on man. is this stock for fucking real? 90k volume only and down 20%. fuck this shit